Fluorescence in situ hybridization (FISH): An increasingly demanded tool for biomarker research and personalized medicine

Biomarker Research

Volumn 2, Issue 1, 2014, Pages

  Hu, Linping ^a,d   Ru, Kun ^a   Zhang, Li ^a   Huang, Yuting ^b   Zhu, Xiaofan ^a,d   Liu, Hanzhi ^a,d   Zetterberg, Anders ^c   Cheng, Tao ^a,d   Miao, Weimin ^a,d  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

^d PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Biomarkers; Fluorescence in situ hybridization (FISH); Genetic aberrations; Hematopoietic malignancies; Personalized medicine; Solid tumors

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; IPILIMUMAB; TRANSCRIPTION FACTOR ERG; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER GENETICS; CANCER PROGNOSIS; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CHRONIC LYMPHATIC LEUKEMIA; DIAGNOSTIC KIT; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; FLUORESCENCE IN SITU HYBRIDIZATION KIT; GENE FUSION; GENETIC SCREENING; HEMATOLOGIC MALIGNANCY; HIGH THROUGHPUT SEQUENCING; HUMAN; LEUKEMIA; LUNG CANCER; MELANOMA; METHODOLOGY; MICROARRAY ANALYSIS; MOLECULAR PROBE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEXT GENERATION SEQUENCING; OVARY CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE MULTIGENE FLUORESCENCE IN SITU HYBRIDIZATION; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; TRISOMY 12; X RAY BONE DENSITOMETER;

EID: 85019461239     PISSN: None     EISSN: 20507771     Source Type: Journal    
DOI: 10.1186/2050-7771-2-3     Document Type: Review

References (97)

1. Wertheim GB, Hexner E, Bagg A. Molecular-based classification of acute myeloid leukemia and its role in directing rational therapy: personalized medicine for profoundly promiscuous proliferations. Mol Diagn Ther 2012, 16(6):357-369. 10.1007/s40291-012-0009-0, 23184342.
2. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med 2013, 5(5):47. 10.1186/gm451, 23731665.
3. Dietel M, Johrens K, Laffert M, Hummel M, Blaker H, Muller BM, Lehmann A, Denkert C, Heppner FL, Koch A, et al. Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther 2013, 20(4):211-221. 10.1038/cgt.2013.13, 23492822.
4. Boyd C, Boyle DP. Molecular diagnosis on tissues and cells: how it affects training and will affect practice in the future. Cytopathology 2012, 23(5):286-294. 10.1111/j.1365-2303.2012.01004.x, 22846108.
5. Jiang H, Xue Y, Wang Q, Pan J, Wu Y, Zhang J, Bai S, Wang Q, He G, Sun A, et al. The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failure. Leuk Res 2012, 36(4):448-452. 10.1016/j.leukres.2011.10.014, 22047706.
6. Pathmanathan N, Bilous AM. HER2 testing in breast cancer: an overview of current techniques and recent developments. Pathology 2012, 44(7):587-595. 10.1097/PAT.0b013e328359cf9a, 23111474.
7. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 2013, 24(9):2364-2370. 10.1093/annonc/mdt220, 23788756.
8. Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol 2013, 8(1):55-67. 10.1007/s11523-012-0250-9, 23325296.
9. Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012, 18(14):3737-3742. 10.1158/1078-0432.CCR-11-2393, 22547770.
10. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243(5405):290-293. 10.1038/243290a0, 4126434.
11. Zhang Y, Rowley JD. Chronic myeloid leukemia: current perspectives. Clin Lab Med 2011, 31(4):687-698. x, 10.1016/j.cll.2011.08.012, 22118744.
12. Latagliata R, Avvisati G, Lo Coco F, Petti MC, Diverio D, Spadea A, Fazi P, Torromeo C, Breccia M, Malagnino F, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly-diagnosed acute promyelocytic leukemia patients aged > 60 years. Ann Oncol 1997, 8(12):1273-1275. 10.1023/A:1008272817839, 9496395.
13. Ablain J, de The H. Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood 2011, 117(22):5795-5802. 10.1182/blood-2011-02-329367, 21444912.
14. Costa D, Vidal A, Carrio A, Munoz C, Arias A, Gomez C, Berneaga D, Colomer D, Rozman M, Pratcorona M, et al. Refining the diagnosis and prognostic categorization of acute myeloid leukemia patients with an integrated use of cytogenetic and molecular studies. Acta Haematol 2013, 129(2):65-71. 10.1159/000343616, 23154527.
15. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011, 25(1):39-51. 10.1016/j.blre.2010.10.002, 21078537.
16. Ritterbach J, Hiddemann W, Beck JD, Schrappe M, Janka-Schaub G, Ludwig WD, Harbott J, Lampert F. Detection of hyperdiploid karyotypes (>50 chromosomes) in childhood acute lymphoblastic leukemia (ALL) using fluorescence in situ hybridization (FISH). Leukemia 1998, 12(3):427-433. 10.1038/sj.leu.2400930, 9529139.
17. Lampert F, Harbott J, Borkhardt A. Cytogenetic aspects of childhood leukemias. Klin Padiatr 2013, 225(Suppl 1):S30-S33.
18. Smoley SA, Brockman SR, Paternoster SF, Meyer RG, Dewald GW. A novel tricolor, dual-fusion fluorescence in situ hybridization method to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with deletion of DNA on the derivative chromosome 9 in chronic myelocytic leukemia. Cancer Genet Cytogenet 2004, 148(1):1-6. 10.1016/S0165-4608(03)00202-4, 14697634.
19. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343(26):1910-1916. 10.1056/NEJM200012283432602, 11136261.
20. Rodriguez-Vicente AE, Diaz MG, Hernandez-Rivas JM. Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. Cancer genetics 2013, 206(3):49-62. 10.1016/j.cancergen.2013.01.003, 23531595.
21. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. Leuk Lymphoma 2013, 54(11):2351-2364. 10.3109/10428194.2013.783913, 23480493.
22. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grunhagen U, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010, 376(9747):1164-1174. 10.1016/S0140-6736(10)61381-5, 20888994.
23. Nilsson T, Hoglund M, Lenhoff S, Rylander L, Turesson I, Westin J, Mitelman F, Johansson B. A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences. Brit J Haematol 2003, 120(6):960-969.
24. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A, Mateo G, Hernandez JM, Perez S, Orfao A, et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004, 104(9):2661-2666. 10.1182/blood-2004-04-1319, 15238415.
25. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C, . Groupe Francais de Cytogenetique H Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001, 98(7):2229-2238. 10.1182/blood.V98.7.2229, 11568011, Groupe Francais de Cytogenetique H.
26. Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet 2011, 204(1):3-12. 10.1016/j.cancergencyto.2010.11.002, 21356186.
27. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002, 2(3):175-187. 10.1038/nrc746, 11990854.
28. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001, 20(40):5611-5622. 10.1038/sj.onc.1204641, 11607813.
29. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R, . Intergroupe Francophone du M Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001, 98(10):3082-3086. 10.1182/blood.V98.10.3082, 11698294, Intergroupe Francophone du M.
30. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, Naucke S, Sawyer JR. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995, 86(11):4250-4256.
31. Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 2001, 15(6):981-986. 10.1038/sj.leu.2402125, 11417487.
32. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998, 92(3):802-809.
33. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003, 101(11):4569-4575. 10.1182/blood-2002-10-3017, 12576322.
34. Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007, 13(9):1066-1072. 10.1016/j.bbmt.2007.05.014, 17697969.
35. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Brit J Haematol 2007, 136(4):615-623.
36. Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007, 109(6):2276-2284. 10.1182/blood-2006-07-038430, 17105813.
37. Kawankar N, Jijina F, Ghosh K, Vundinti BR. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes. Cancer Epidemiol 2011, 35(4):e1-e5. 10.1016/j.canep.2010.11.009, 21193364.
38. Voso MT, Fenu S, Latagliata R, Buccisano F, Piciocchi A, Aloe-Spiriti MA, Breccia M, Criscuolo M, Andriani A, Mancini S, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO prognostic scoring system: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013, 31(21):2671-2677. 10.1200/JCO.2012.48.0764, 23796988.
39. Adema V, Hernandez JM, Abaigar M, Lumbreras E, Such E, Calull A, Dominguez E, Arenillas L, Mallo M, Cervera J, et al. Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: does -7/7q- detection by FISH have prognostic value?. Leuk Res 2013, 37(4):416-421. 10.1016/j.leukres.2012.12.010, 23337401.
40. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25(7):1147-1152. 10.1038/leu.2011.71, 21494260.
41. Otrock ZK, Tiu RV, Maciejewski JP, Sekeres MA. The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication?. Expert Rev Hematol 2013, 6(1):59-68. 10.1586/ehm.12.67, 23373781.
42. Weickhardt AJ, Aisner DL, Franklin WA, Varella-Garcia M, Doebele RC, Camidge DR. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013, 119(8):1467-1477. 10.1002/cncr.27913, 23280244.
43. Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19(15):4273-4281. 10.1158/1078-0432.CCR-13-0318, 3874127, 23729361.
44. Savic S, Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012, 56(6):611-621. 10.1159/000339792, 23207439.
45. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, Asamura H, Furuta K, Shibata T, Tsuda H. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013, 37(4):554-562. 10.1097/PAS.0b013e3182758fe6, 23426121.
46. Rothschild SI, Gautschi O. Crizotinib in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2013, 14(5):473-480. 10.1016/j.cllc.2013.04.006, 23790969.
47. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res 2009, 15(14):4706-4711. 10.1158/1078-0432.CCR-08-2927, 3717524, 19584163.
48. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D, Foster CS, Fletcher A, Gerald WL, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27(3):253-263. 10.1038/sj.onc.1210640, 2646890, 17637754.
49. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007, 26(31):4596-4599. 10.1038/sj.onc.1210237, 17237811.
50. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, Al-Ahmadie HA, Fine SW, Eastham JA, Scardino PT, Scher HI, Tickoo SK, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009, 69(4):1400-1406. 10.1158/0008-5472.CAN-08-2467, 3676271, 19190343.
51. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008, 14(11):3395-3400. 10.1158/1078-0432.CCR-07-2051, 18519769.
52. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987, 7(5):2019-2023. 365313, 3299059.
53. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712. 10.1126/science.2470152, 2470152.
54. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in breast cancer. Oncology 2001, 61(Suppl 2):67-72.
55. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685. 10.1158/1078-0432.CCR-04-2421, 16115903.
56. Cleator S, Ashworth A. Molecular profiling of breast cancer: clinical implications. Brit J Cancer 2004, 90(6):1120-1124. 10.1038/sj.bjc.6601667, 2409657, 15026788.
57. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
58. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
59. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006, 16(12):1465-1479. 10.1101/gr.5460106, 1665631, 17142309.
60. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10(6):529-541. 10.1016/j.ccr.2006.10.009, 17157792.
61. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, et al. Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96. 10.1186/1471-2407-6-96, 1459181, 16620391.
62. Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, Tibshirani R, Borresen-Dale AL, Pollack JR. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Gene Chromosome Canc 2006, 45(11):1033-1040.
63. Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, et al. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC cancer 2006, 6:245. 10.1186/1471-2407-6-245, 1626089, 17040570.
64. Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009, 114(2):287-299. 10.1007/s10549-008-0017-2, 2635926, 18425577.
65. Carracedo A, Salido M, Corominas JM, Rojo F, Ferreira BI, Suela J, Tusquets I, Corzo C, Segura M, Espinet B, et al. Are ER+PR+ and ER+PR- breast tumors genetically different? A CGH array study. Cancer Genet 2012, 205(4):138-146. 10.1016/j.cancergen.2012.01.001, 22559974.
66. Ly M, Valent A, Diallo G, Penault-Lorca F, Dumke K, Marty V, Viehl P, Lazar V, Job B, Richon C, et al. Gene copy number variations in breast cancer of Sub-Saharan African women. Breast 2013, 22(3):295-300. 10.1016/j.breast.2012.07.010, 22999459.
67. Ioannidis P, Mahaira L, Papadopoulou A, Teixeira MR, Heim S, Andersen JA, Evangelou E, Dafni U, Pandis N, Trangas T. 8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. Int J Cancer 2003, 104(1):54-59. 10.1002/ijc.10794, 12532419.
68. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Gene Chromosome Canc 1994, 9(1):42-48.
69. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 2009, 15(1):9-20. 10.1016/j.ccr.2008.11.013, 2676231, 19111877.
70. Walker LC, McDonald M, Wells JE, Harris GC, Robinson BA, Morris CM. Dual-color fluorescence in situ hybridization reveals an association of chromosome 8q22 but not 8p21 imbalance with high grade invasive breast carcinoma. PloS One 2013, 8(7):e70790. 10.1371/journal.pone.0070790, 3723675, 23936250.
71. Mesquita B, Lopes P, Rodrigues A, Pereira D, Afonso M, Leal C, Henrique R, Lind GE, Jeronimo C, Lothe RA, et al. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. Breast Cancer Res Treat 2013, 138(1):37-45. 10.1007/s10549-013-2408-2, 23329352.
72. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486(7403):346-352. 3440846, 22522925.
73. Shahbain H, Cooper C, Gerami P. Molecular diagnostics for ambiguous melanocytic tumors. Semin Cutan Med Surg 2012, 31(4):274-278. 10.1016/j.sder.2012.09.001, 23174498.
74. Nijhawan RI, Votava HJ, Mariwalla K. Clinical application and limitations of the fluorescence in situ hybridization (FISH) assay in the diagnosis and management of melanocytic lesions: a report of 3 cases. Cutis 2012, 90(4):189-195.
75. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998, 58(10):2170-2175.
76. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003, 163(5):1765-1770. 10.1016/S0002-9440(10)63536-5, 1892437, 14578177.
77. Horst BA, Fang Y, Silvers DN, Busam KJ. Chromosomal aberrations by 4-color fluorescence in situ hybridization not detected in Spitz nevi of older individuals. Arch Dermatol 2012, 148(10):1152-1156. 10.1001/archdermatol.2012.2267, 23069951.
78. Bangash HK, Romegialli A, Dadras SS. What's new in prognostication of melanoma in the dermatopathology laboratory?. Clin Dermatol 2013, 31(3):317-323. 10.1016/j.clindermatol.2012.08.007, 23608451.
79. Julia F, Thomas L, Dalle S. New therapeutical strategies in the treatment of metastatic disease. Dermatol Ther 2012, 25(5):452-457. 10.1111/j.1529-8019.2012.01487.x, 23046024.
80. Pajor G, Alpar D, Kajtar B, Melegh B, Somogyi L, Kneif M, Bollmann D, Pajor L, Sule N. Automated signal pattern evaluation of a bladder cancer specific multiprobe-fish assay applying a user-trainable workstation. Microsc Res Tech 2012, 75(6):814-820. 10.1002/jemt.21131, 22615107.
81. Raimondo F, Gavrielides MA, Karayannopoulou G, Lyroudia K, Pitas I, Kostopoulos I. Automated evaluation of Her-2/neu status in breast tissue from fluorescent in situ hybridization images. IEEE Trans Image Process 2005, 14(9):1288-1299.
82. Theodosiou Z, Kasampalidis IN, Karayannopoulou G, Kostopoulos I, Bobos M, Bevilacqua G, Aretini P, Starita A, Lyroudia K, Pitas I. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. Breast 2008, 17(1):80-84. 10.1016/j.breast.2007.07.041, 17889539.
83. Kilpatrick MW, Sheehan CE, Marganski WA, Tafas T, Ross MS, Ross JS. Determination of HER2 gene status by fully automated fluorescence microscopy. Anal Quant Cytol Histol 2011, 33(4):205-210.
84. Kajtar B, Mehes G, Lorch T, Deak L, Kneifne M, Alpar D, Pajor L. Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei. Cytometry A 2006, 69(6):506-514.
85. Stumm M, Wegner RD, Bloechle M, Eckel H. Interphase M-FISH applications using commercial probes in prenatal and PGD diagnostics. Cytogenet Genome Res 2006, 114(3-4):296-301.
86. Chyhrai A, Sanjmyatav J, Gajda M, Reichelt O, Wunderlich H, Steiner T, Tanovic E, Junker K. Multi-colour FISH on preoperative renal tumour biopsies to confirm the diagnosis of uncertain renal masses. World J Urol 2010, 28(3):269-274. 10.1007/s00345-010-0551-5, 20390284.
87. Schramm M, Wrobel C, Born I, Kazimirek M, Pomjanski N, William M, Kappes R, Gerharz CD, Biesterfeld S, Bocking A. Equivocal cytology in lung cancer diagnosis: improvement of diagnostic accuracy using adjuvant multicolor FISH, DNA-image cytometry, and quantitative promoter hypermethylation analysis. Cancer Cytopathol 2011, 119(3):177-192. 10.1002/cncy.20142, 21413159.
88. Anderson K, Lutz C, van Delft FW, Bateman CM, Guo Y, Colman SM, Kempski H, Moorman AV, Titley I, Swansbury J, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 2011, 469(7330):356-361. 10.1038/nature09650, 21160474.
89. Janssens A, Van Roy N, Poppe B, Noens L, Philippe J, Speleman F, Offner F. High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. Eur J Haematol 2012, 89(1):72-80. 10.1111/j.1600-0609.2012.01790.x, 22509718.
90. Wawrzyniak E, Kotkowska A, Blonski JZ, Siemieniuk-Rys M, Ziolkowska E, Giannopoulos K, Robak T, Korycka-Wolowiec A. Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. Eur J Haematol 2013, 92(2):91-101.
91. Wang YC, Hu LP, Lin D, Li CW, Yuan T, Jia YJ, Tian Z, Tang KJ, Wang M, Wang JX. Detection of heterogeneity and evolution of subclones in t(8;21) AML by QM-FISH. Zhonghua Xue Ye Xue Za Zhi 2013, 34(10):844-850.
92. Vital AL, Tabernero MD, Crespo I, Rebelo O, Tao H, Gomes F, Lopes MC, Orfao A. Intratumoral patterns of clonal evolution in gliomas. Neurogenetics 2010, 11(2):227-239. 10.1007/s10048-009-0217-x, 19760258.
93. Zhang S, Shao Y, Hou G, Bai J, Yuan W, Hu L, Cheng T, Zetterberg A, Zhang J. QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer. Tumour Biol 2013, (Epub ahead of print).
94. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res 2013, 32:48. 10.1186/1756-9966-32-48, 3734167, 23902592.
95. Li Z. CD133: a stem cell biomarker and beyond. Exp Hematol Oncol 2013, 2(1):17. 10.1186/2162-3619-2-17, 3701589, 23815814.
96. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ. Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia. Gene Chromosome Canc 2010, 49(12):1104-1113.
97. Cheng T. Cell cycle inhibitors in normal and tumor stem cells. Oncogene 2004, 23(43):7256-7266. 10.1038/sj.onc.1207945, 15378085.